News
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...
Asianet Newsable on MSN1d
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy
BofA Securities raised its target to $64 with a ‘Buy’ rating, while Stifel lifted its target to $43 with a ‘Hold,’ both ...
Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $62 and keeps an Overweight rating on the shares ...
Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback